307 related articles for article (PubMed ID: 33826405)
1. Next-generation inward rectifier potassium channel modulators: discovery and molecular pharmacology.
Weaver CD; Denton JS
Am J Physiol Cell Physiol; 2021 Jun; 320(6):C1125-C1140. PubMed ID: 33826405
[TBL] [Abstract][Full Text] [Related]
2. Discovery, Characterization, and Effects on Renal Fluid and Electrolyte Excretion of the Kir4.1 Potassium Channel Pore Blocker, VU0134992.
Kharade SV; Kurata H; Bender AM; Blobaum AL; Figueroa EE; Duran A; Kramer M; Days E; Vinson P; Flores D; Satlin LM; Meiler J; Weaver CD; Lindsley CW; Hopkins CR; Denton JS
Mol Pharmacol; 2018 Aug; 94(2):926-937. PubMed ID: 29895592
[TBL] [Abstract][Full Text] [Related]
3. Screening Technologies for Inward Rectifier Potassium Channels: Discovery of New Blockers and Activators.
Walsh KB
SLAS Discov; 2020 Jun; 25(5):420-433. PubMed ID: 32292089
[TBL] [Abstract][Full Text] [Related]
4. High-throughput screening for small-molecule modulators of inward rectifier potassium channels.
Raphemot R; Weaver CD; Denton JS
J Vis Exp; 2013 Jan; (71):. PubMed ID: 23381507
[TBL] [Abstract][Full Text] [Related]
5. ML418: The First Selective, Sub-Micromolar Pore Blocker of Kir7.1 Potassium Channels.
Swale DR; Kurata H; Kharade SV; Sheehan J; Raphemot R; Voigtritter KR; Figueroa EE; Meiler J; Blobaum AL; Lindsley CW; Hopkins CR; Denton JS
ACS Chem Neurosci; 2016 Jul; 7(7):1013-23. PubMed ID: 27184474
[TBL] [Abstract][Full Text] [Related]
6. VU6036720: The First Potent and Selective In Vitro Inhibitor of Heteromeric Kir4.1/5.1 Inward Rectifier Potassium Channels.
McClenahan SJ; Kent CN; Kharade SV; Isaeva E; Williams JC; Han C; Terker A; Gresham R; Lazarenko RM; Days EL; Romaine IM; Bauer JA; Boutaud O; Sulikowski GA; Harris R; Weaver CD; Staruschenko A; Lindsley CW; Denton JS
Mol Pharmacol; 2022 May; 101(5):357-370. PubMed ID: 35246480
[TBL] [Abstract][Full Text] [Related]
7. Discovery, characterization, and structure-activity relationships of an inhibitor of inward rectifier potassium (Kir) channels with preference for Kir2.3, Kir3.x, and Kir7.1.
Raphemot R; Lonergan DF; Nguyen TT; Utley T; Lewis LM; Kadakia R; Weaver CD; Gogliotti R; Hopkins C; Lindsley CW; Denton JS
Front Pharmacol; 2011; 2():75. PubMed ID: 22275899
[TBL] [Abstract][Full Text] [Related]
8. Small-molecule modulators of inward rectifier K+ channels: recent advances and future possibilities.
Bhave G; Lonergan D; Chauder BA; Denton JS
Future Med Chem; 2010 May; 2(5):757-74. PubMed ID: 20543968
[TBL] [Abstract][Full Text] [Related]
9. High-throughput screening reveals a small-molecule inhibitor of the renal outer medullary potassium channel and Kir7.1.
Lewis LM; Bhave G; Chauder BA; Banerjee S; Lornsen KA; Redha R; Fallen K; Lindsley CW; Weaver CD; Denton JS
Mol Pharmacol; 2009 Nov; 76(5):1094-103. PubMed ID: 19706730
[TBL] [Abstract][Full Text] [Related]
10. Selective inhibition of the K(ir)2 family of inward rectifier potassium channels by a small molecule probe: the discovery, SAR, and pharmacological characterization of ML133.
Wang HR; Wu M; Yu H; Long S; Stevens A; Engers DW; Sackin H; Daniels JS; Dawson ES; Hopkins CR; Lindsley CW; Li M; McManus OB
ACS Chem Biol; 2011 Aug; 6(8):845-56. PubMed ID: 21615117
[TBL] [Abstract][Full Text] [Related]
11. Cardiac and renal inward rectifier potassium channel pharmacology: emerging tools for integrative physiology and therapeutics.
Swale DR; Kharade SV; Denton JS
Curr Opin Pharmacol; 2014 Apr; 15():7-15. PubMed ID: 24721648
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of fluorescence-based and automated patch clamp-based functional assays for the inward rectifier potassium channel Kir4.1.
Raphemot R; Kadakia RJ; Olsen ML; Banerjee S; Days E; Smith SS; Weaver CD; Denton JS
Assay Drug Dev Technol; 2013; 11(9-10):532-43. PubMed ID: 24266659
[TBL] [Abstract][Full Text] [Related]
13. Pore Polarity and Charge Determine Differential Block of Kir1.1 and Kir7.1 Potassium Channels by Small-Molecule Inhibitor VU590.
Kharade SV; Sheehan JH; Figueroa EE; Meiler J; Denton JS
Mol Pharmacol; 2017 Sep; 92(3):338-346. PubMed ID: 28619748
[TBL] [Abstract][Full Text] [Related]
14. Targeting the inward-rectifier potassium channel ROMK in cardiovascular disease.
Garcia ML; Kaczorowski GJ
Curr Opin Pharmacol; 2014 Apr; 15():1-6. PubMed ID: 24721647
[TBL] [Abstract][Full Text] [Related]
15. A High-Throughput Electrophysiology Assay Identifies Inhibitors of the Inwardly Rectifying Potassium Channel Kir7.1.
Wright PD; Kanumilli S; Tickle D; Cartland J; Bouloc N; Dale T; Tresize DJ; McCloskey C; McCavera S; Blanks AM; Kettleborough C; Jerman JC
J Biomol Screen; 2015 Jul; 20(6):739-47. PubMed ID: 25656238
[TBL] [Abstract][Full Text] [Related]
16. Development of a selective small-molecule inhibitor of Kir1.1, the renal outer medullary potassium channel.
Bhave G; Chauder BA; Liu W; Dawson ES; Kadakia R; Nguyen TT; Lewis LM; Meiler J; Weaver CD; Satlin LM; Lindsley CW; Denton JS
Mol Pharmacol; 2011 Jan; 79(1):42-50. PubMed ID: 20926757
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Small Molecule Renal Outer Medullary Potassium (ROMK) Channel Inhibitors: A Brief History of Medicinal Chemistry Approaches To Develop Novel Diuretic Therapeutics.
Aretz CD; Vadukoot AK; Hopkins CR
J Med Chem; 2019 Oct; 62(19):8682-8694. PubMed ID: 31034224
[TBL] [Abstract][Full Text] [Related]
18. Kir Channel Blockages by Proflavine Derivatives via Multiple Modes of Interaction.
Inanobe A; Itamochi H; Kurachi Y
Mol Pharmacol; 2018 Jun; 93(6):592-600. PubMed ID: 29650538
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
